Your browser doesn't support javascript.
loading
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Zhao, Yizhuo; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Luo, Yi; Wu, Lin; Wang, Xiuwen; Nan, Kejun; Jin, Faguang; Dong, Jian; Li, Baolan; Yamaguchi, Fumihiro; Breadner, Daniel; Nagano, Tatsuya; Tanaka, Fumihiro; Husain, Hatim; Li, Kai; Han, Baohui.
Afiliación
  • Zhao Y; Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Wang Q; Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang L; Department of Internal Medicine, Henan Cancer Hospital, Zhengzhou, China.
  • Shi J; Department of Respiratory Diseases, Peking Union Medical College Hospital, Beijing, China.
  • Wang Z; Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China.
  • Cheng Y; Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan, China.
  • He J; Department of Thoracic Medical Oncology, Jilin Cancer Hospital, Changchun, China.
  • Shi Y; Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Chen W; Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
  • Luo Y; Department of Pulmonary Medicine, Lanzhou Military General Hospital, Lanzhou, China.
  • Wu L; Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China.
  • Wang X; Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China.
  • Nan K; Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China.
  • Jin F; Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Dong J; Department of Respiratory Diseases, Tang Du Hospital, Xi'an, China.
  • Li B; First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China.
  • Yamaguchi F; Department of General Medicine, Capital Medical University, Beijing Chest Hospital, Beijing, China.
  • Breadner D; Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Nagano T; Division of Medical Oncology, London Regional Cancer Program at London Health Science Center, London, Canada.
  • Tanaka F; Schulich School of Medicine and Dentistry at Western University, London, Canada.
  • Husain H; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Li K; Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Han B; Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Transl Lung Cancer Res ; 11(5): 776-785, 2022 May.
Article en En | MEDLINE | ID: mdl-35693290
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2022 Tipo del documento: Article País de afiliación: China